Histopathological Characterization and Whole Exome Sequencing of Ectopic Thyroid: Fetal Architecture in a Functional Ectopic Gland from Adult Patient.

Ectopic thyroid results from a migration defect of the developing gland during embryogenesis causing congenital hypothyroidism. But it has also been detected in asymptomatic individuals. This study aimed to investigate the histopathological, functional, and genetic features of human ectopic thyroids. Six samples were histologically examined, and the expression of the specific thyroid proteins was assessed by immunohistochemistry. Two samples were submitted to whole exome sequencing. An oropharynx sample showed immature fetal architecture tissue with clusters or cords of oval thyrocytes and small follicles; one sample exhibited a normal thyroid pattern while four showed colloid goiter. All ectopic thyroids expressed the specific thyroid genes and T4 at similar locations to those observed in normal thyroid. No somatic mutations associated with ectopic thyroid were found. This is the first immature thyroid fetal tissue observed in an ectopic thyroid due to the arrest of structural differentiation early in the colloid stage of development that proved able to synthesize thyroid hormone but not to respond to TSH. Despite the ability of all ectopic thyroids to synthetize specific thyroid proteins and T4, at some point in life, it may be insufficient to support body growth leading to hypothyroidism, as observed in some of the patients.

Evaluation and clinical application of changes in thyroid hormone and TSH levels in critically ill full-term newborns.

INTRODUCTION: The term "euthyroid sick syndrome" (ESS) has been used to describe a pattern of thyroid hormone changes during the course of critical illness in adult patients without thyroid disease, often associated with reduced thyroid hormone secretion. OBJECTIVE: To describe the thyroid hormone profile in full-term newborns critically ill compared with thyroid hormone profile of healthy infants, and determine if alterations could be related to the severity of the disease and outcome. METHODS: A cross-sectional, observational, and prospective study of full-term infants admitted to the neonatal intensive care unit (NICU) of the Hospital de Pediatría J.P. Garrahan between July 2007 and April 2008. Serum T3, T4, and thyroid stimulating hormone (TSH) levels were measured at admission and severity of the disease was evaluated through SNAP, lactic acid, respiratory assistance and number of organs affected. RESULTS: Sick newborns showed significantly lower T3 and T4 levels compared with healthy infants [T3: -0.97 µg/dL (95% CI -0.89, -1.13) and T4: -4.37 µg/dL (95% CI -2.95, -5.78)]. Only 29 out of 94 (31%) infants presented a normal profile; 37 (39%) infants showed isolated low T3 levels, 20 (21%) infants had low T3 and T4 levels and eight (9%) infants had low TSH, T3, and T4. Of this latter group, five of eight (62%) children died suggesting a significantly higher risk of death for patients with low T3 associated with low T4 and TSH [Risk ratio (RR) 10.75 95% CI 3.93, 29]. CONCLUSIONS: Full-term sick newborns frequently have lower thyroid hormone levels than healthy ones. These observed thyroid hormones changes might be related to the underlying disease and could be used as a prognostic marker of the severity and fatal outcome of the patient.

Genotyping of resistance to thyroid hormone in South American population. Identification of seven novel missense mutations in the human thyroid hormone receptor beta gene.

Thyroid Hormone Receptor beta (THRB) defects, typically transmitted as autosomal dominant traits, cause Resistance to Thyroid Hormone (RTH). We analyzed the THRB gene in thirteen South American patients with clinical evidence RTH from eleven unrelated families. Sequence analysis revealed seven novel missense mutations. Four novel mutations were identified in exon 9. The first, a c.991A>G transition which originates a substitution of asparagine by aspartic acid (p.N331D). The second nucleotide alteration consists of a guanine to cytosine transversion at position 1003 (c.1003G>C) and results in substitution of the alanine at codon 335 by proline (p.A335P). The third mutation, a c.1022T>C transition produces a change of leucine by proline (p.L341P). The fourth mutation detected in exon 9 was a c.1036C>T transition which replaces the leucine at codon 346 by phenylalanine (p.L346F). The sequencing of the exon 10 detected three novel missense mutations. The first, a c.1293A>G transition changing isoleucine 431 for methionine (p.I431M). The second, the cytosine at position 1339 was replaced by adenine (c.1339C>A) resulting in the replacement of proline by threonine (p.P447T). The third mutation detected in exon 10 was a c.1358C>T transition resulting in the substitution of proline at codon 453 by leucine (p.P453L). Finally, sequencing analysis of the THRB gene revealed three substitutions previously described (p.A268G, p.P453T and p.F459C). The p.P453T was found in two patients. In conclusion, we report thirteen patients with RTH caused by heterozygous mutations of the THRB gene. Seven of the identified mutations correspond to novel substitutions.

Identification and characterization of four PAX8 rare sequence variants (p.T225M, p.L233L, p.G336S and p.A439A) in patients with congenital hypothyroidism and dysgenetic thyroid glands.

CONTEXT: Thyroid dysgenesis may be associated with mutations in the paired box transcription factor 8 (PAX8) gene and is characterized by congenital hypothyroidism transmitted in an autosomal dominant mode. OBJECTIVES: The aim of this study was to identify new mutations in the PAX8 gene. Sixty congenital hypothyroidism-affected individuals with dysgenetic (agenesis, ectopia and hypoplasia) and eutopic thyroid glands were studied. METHODS: The 12 exons of the PAX8 gene along with their exon-intron boundaries were amplified from genomic DNA and a mutational screening was performed by single-strand conformational polymorphism (SSCP) followed by direct sequencing of samples with abnormal migration patterns. The PAX8 mutations were functionally characterized by transient transfection experiments. RESULTS: Molecular analysis of the PAX8 gene indicated that four affected individuals had four sequence differences: three novel variations [c.699C>T (p.L233L), c.1006G>A (p.G336S) and c.1317A>G (p.A439A)] and one recently reported [c.674C>T (p.T225M)], whereas the 56 remaining patients showed only wild-type alleles of PAX8. p.T225M, p.L233L and p.G336S variants were not detected in 530 chromosomes from 265 subjects randomly selected from the general population, whereas the p.A439A variant was identified in only one of the 530 chromosomes analysed. Functional analysis of the nonsynonymous substitutions showed that the p.T225M and p.G336S proteins had not lost their ability to bind a specific DNA sequence and to activate the transcription of the thyroglobulin (TG) promoter in synergy with thyroid transcription factor 1 (TTF1). CONCLUSIONS: We report the occurrence of two nonsynonymous substitutions, one recently reported (p.T225M) and one novel (p.G336S), and two novel synonymous substitutions (p.L233L and p.A439A) in the PAX8 gene. p.T225M and p.G336S are rare sequence variants or may act by inhibiting an unknown particular function. Our study also confirms the very low prevalence of PAX8 mutations in thyroid dysgenesis.

The C105fs114X is the prevalent thyrotropin beta-subunit gene mutation in Argentinean patients with congenital central hypothyroidism.

BACKGROUND: Congenital isolated thyrotropin (TSH) deficiency is an unusual condition characterized by low levels of thyroid hormones and TSH, usually presenting early typical signs of severe hypothyroidism. Five different beta-TSH mutations have been described so far. While 4 of them affect only consanguineous families, a frameshift mutation in exon 3 (C105fs114X) has been found also in nonconsanguineous families. OBJECTIVE: The aim of the present study was to characterize beta-TSH mutations in Argentinean patients with congenital central hypothyroidism (CCH) and to emphasize the importance of early biochemical and molecular diagnosis of this disorder. PATIENTS AND METHODS: We investigated 8 Argentinean children (3 boys, 5 girls) from 7 unrelated families with CCH based upon low levels of T(4) and T(3), and low basal and stimulated TSH levels. Mutation characterizations for the beta-TSH gene were performed by PCR amplification followed by sequence and restriction enzyme analysis with SNABI in the patients, 9 parents and in 100 newborn children. RESULTS: All patients presented the same homozygous mutation in exon 3 of the beta-TSH gene (C105fs114X), the 9 studied parents were heterozygous for the same mutation and 1 carrier was found in the 100 studied newborns. CONCLUSION: Our findings show that the C105fs114X mutation is prevalent in our population and may constitute a hot spot at codon 105 in the beta-TSH gene. Since this mutation is easily demonstrable by a SNABI digestion in DNA amplified from dried blood spots, its investigation would be indicated in patients in our milieu with clinical and biochemical features of CCH, allowing early L-thyroxine (LT(4)) replacement and genetic counseling of the family.

Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.

BACKGROUND: Multiple endocrine neoplasia type 2 (MEN 2) is an inherited disease caused by germline mutations in the RET proto-oncogene, and is responsible for the development of endocrine neoplasia. Its prognosis is dependent on the appearance and spread of medullary thyroid carcinoma (MTC). Relatives at risk can be identified before clinical or biochemical signs of the disease become evident. METHODS: Twenty-one families with MEN 2 (16 families with MEN 2A and 5 families with MEN 2B) were studied. Peripheral blood DNA was amplified by polymerase chain reaction. DNA sequence or restriction enzyme analysis was performed to detect mutations of RET proto-oncogene exons 10, 11, and 16. Molecular analysis was carried out in all index patients as well as in 98 relatives of MEN 2A patients (60 juveniles, ages 6 months to 21 years, and 38 adults, ages 22 to 81 years) and in 13 relatives (6 juveniles ages 10 to 21 years, and 7 adults ages 41 to 66 years) from MEN 2B families. RESULTS: Molecular studies showed a mutation at codon 634, exon 11 in all MEN 2A patients. All MEN 2B patients showed an ATG to ACG (Met918Thr) mutation. In MEN 2A families, 42 out of 98 relatives were affected. Total thyroidectomy was performed in 18 juvenile carriers ages 17 months to 21 years. Histopathologic studies of the glands revealed parafollicular cell (C-cell) hyperplasia in all of these carriers, medullary thyroid carcinoma in 15 carriers, and only one carrier with lymph node metastases. CONCLUSIONS: The consistent finding of C-cell disease in all the juvenile carriers who underwent preventive thyroidectomy emphasizes the relevance of early screening in children at risk of developing MTC. The presence of MTC in the specimen of prophylactic thyroidectomy from a 17 month old girl highlights the importance of thyroidectomy as soon as the molecular diagnosis is confirmed.

Diagnostico precoz de neoplasia endocrina multiple tipo 2 (MEN 2) por la deteccion de portadores de mutaciones en el proto-oncogen RET / Early diagnosis of multiple endocrine neoplasia type 2 by detection of matated RET proto-oncogene carriers

El MEN 2 es un síndrome hereditario autosómico dominante, en el cual mutaciones del RET dan origen a tres fenotipos diferentes: carcinoma medular de tiroides familiar (CMTF), MEN 2A y MEN 2B. La identificación de mutaciones en el proto-oncogen RET predice el desarrollo de la enfermedad antes de las evidencias clínicas y bioquímicas. En este trabajo se identificaron portadores del RET por caracterización de mutaciones en pacientes y sus familiares. Se estudiaron 21 familias con CMTF (5 y 6 miembros), 4 con MEN 2A (dos de 5, una de 4 y otra de 3 miembros) y 2 con MEN 2B (5 y 1 miembros). Se obtuvieron muestras de ADN de sangre, en todos los casos y de tejido de feocromocitoma y/o tejido tiroideo en los operados. Se utilizó PCR para amplificar los exones 10, 11 y 16 con oligonucleótidos específicos, realizándose secuenciación directa de los fragmentos. En las familias con CMTF y con MEN 2A se encontraron mutaciones en el codón 634 del exón 11 en 16 sujetos, dectándose 9 casos con la mutación TGC r CGC (cisteína a arginina), 3 con TGC r TAC (cisteína a tirosina) y 4 con TGC r TTC (cisteína a fenilalanina). En los pacientes con MEN 2 B se encontró una mutación en el codón 918 del exón 16 ATG r ACG (meitonina a treonina). En tejido tumoral se detectó la misma mutación que en sangre periférica. El diagnóstico de MEN 2 fue confirmado en los 8 pacientes y detectado en 10 familiares. En los 5 portadores tiroidectomizados se encontró hiperplasia de células C o microcarcinoma in situ en 2 niños (9 y 12 años) y CMT en 3 adultos. La detección temprana de mutaciones del RET, especialmente en familiares seguida por tiroidectomía total, podría prevenir el desarrollo de CMT, modificado el desenlace fatal que ocurre cuando es diagnosticado tardíamente.

Normalization of serum sex hormone-binding globulin by L-thyroxine in obese women

La obesidad se asocia con disminución de los niveles séricos de SHBC cuyo origen se desconoce. Se bien las mujeres obesas no presentan evidencias bioquímicas de disminución de la función tiroidea, dado que las hormonas tiroideas aumentan los niveles séricos de la SHBG, se estudió en un grupo de mujeres con obesidad moderada la respuesta de esta proteína a la administración de hormona tiroidea (1-T4). La SHBG sérica aumentó de 44,9 ñ 14,2 (media ñ ES) a 77 ñ 139 nmol/l en 10 mujees obesas luego del tratamiento durante 1 mes con 1-T4 a ladosis de 2,25 ñ 0,58 microng/Kg de peso corporal (p < 0,01). No se observaron cambios en los niveles séricos de la SHBG en mujeres normales con tratamiento similar, mientras que los valores obtenidos en un grupo de pacientes hipotiroideas fueron de 24,2 ñ 3,2 y 60 ñ 9,26 nmol/l, respectivamente (p < 0,01) (Fig. 1). Los niveles de T4 y T3 bajo 1-T4 fueron normales en los 3 grupos de pacientes, así como los niveles séricos de la T4 libre en las obesas. Dado que el comportamiento de las obesas fue similar al de los sujetos hipotiroideos, se especula la posibilidad de que pueda existir una disfunción tiroidea hepática que justifique en parte la disminución de los niveles séricos de la SHBG que se observan en la obesidad. Independientemente del mecanismo, nosotros hemos hallado que los niveles séricos de la SHBG en las mujeres obesas pueden se normalizados luego de la administración de dosis fisológicas de hormona tiroidea

Detección temprana de hipotiroidismo congénito en una población de recién nacidos de riesgo / Early detection of congenital hypothyroidism in a population of high risk newborn

El beneficio de um diagnóstico y tratamiento precoces del hipotiroidismo congénito (HC) en el desarrollo mental ha llevado, en numerosos países, a implementar programas de detección en recién nacidos. Dadas las dificultades de su realización en nuestro medio, hemos desarrollado como alternativa la detección en una población preseleccionada de recién nacidos de riesgo. Determinamos radioinmunológicamente la tirotrofina (TSH) en gotas de sangre recolectadas a partir del 3er día de vida en papel de filtro en recién nacidos provenientes de 6 maternidades de Capital Federal y Gran Buenos Aires, en los que se distribuyeron formularios para realizar la selección sobre la base de signos precoces de HC. El programa fue planeado para el período neonatal; sin embargo recibimos muestras de niños de hasta 1 año de edad. Entre el 1§ de enero de 1979 y el 31 de octubre de 1984 se detectaron 72 hipotiroideos congénitos en 2.508 muestras estudiadas. La distribución por edades de las muestras y de los hipotiroideos detectados fue la siguiente: grupo I (3-30 d) 1.575 con 17 hipotiroideos; grupo II (31-60 d) 468 con 16 hipotiroideos; grupo IV (61d-6m) 311 con 27 hipotiroideos y grupo IV (> 6-12 m) 154 con 12 hipotiroideos. Los signos más frecuentes que determinaron el estudio en el período neonatal fueron: ictericia prolongada (77%), hernia umbilical y/o caída tardía del cordón (65%) y constipación (41%). Este programa constituve la mejor segunda alternativa frente a la pesquisa masiva y contribuye a disminuir la edad de diagnóstico del HC en nuestro medio y a crear la conciencia en el pediatra y en los padres de la importancia de la detección y tratamiento precoces del HC en estos niños que, de otro modo, desarrollarán daño mental irreversible